Prosecution Insights
Last updated: October 01, 2026

Examiner: LUSI, ELLIS FOLLETT

Tech Center 1600 • Art Units: 1636 1672 1677 1678

This examiner grants 64% of resolved cases

Analysis

Ellis Follett Lusi is an examiner in Tech Center 1600 and Art Unit 1636. The examiner has 74 resolved cases. The allowance rate pct is 63.5, and the interview lift pct is 53.4. The median days to allowance is 1439. This 1439-day figure is the median time for an application to reach allowance. The 63.5 percent allowance rate indicates the frequency of successful outcomes. The 53.4 percent interview lift pct suggests that interviews are a very effective tool for practitioners.

With 74 resolved cases, the 63.5 percent allowance rate is a reliable indicator of prosecution success. The 53.4 percent interview lift pct provides a strong strategic advantage for applicants in Art Unit 1636. The 1439 days to allowance reflects the timeline for prosecution in Tech Center 1600. The 63.5 percent allowance rate is a key metric for evaluating the likelihood of a grant. The 74 resolved cases provide a sufficient basis for these statistics. The 1439 days to allowance is a specific benchmark for pendency.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

63.5%
Allow Rate
+3.5% vs TC avg
111
Total Applications
+53.4%
Interview Lift
1439
Avg Prosecution Days
Based on 74 resolved cases, 2023–2026

Rejection Statute Breakdown

6.8%
§101 Eligibility
16.0%
§102 Novelty
33.1%
§103 Obviousness
31.0%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17389675 REAGENT KIT, MEASUREMENT KIT, AND MEASUREMENT METHOD Final Rejection FUJIFILM Corporation
17279025 HIGH THROUGHPUT EPITOPE IDENTIFICATION AND T CELL RECEPTOR SPECIFICITY DETERMINATION USING LOADABLE DETECTION MOLECULES Non-Final OA 10x Genomics, Inc.
18173002 ASSAYS AND REAGENTS FOR CHARACTERIZATION OF MHCI PEPTIDE BINDING Final Rejection GENENTECH, INC.
18252605 DEVELOPMENT OF A NOVEL ELISA-BASED POINT-OF-CARE ANTIGEN TEST FOR SARS-COV-2 Non-Final OA The Regents of the University of California
18029606 HIGH-THROUGHPUT METHOD FOR LP(A)-CHOLESTEROL QUANTITATION Non-Final OA The Regents of the University of California
18276885 LATERAL FLOW TEST DEVICE Non-Final OA ams-OSRAM AG
16932533 MULTIPLEX LATERAL FLOW ASSAY FOR DIFFERENTIATING BACTERIAL INFECTIONS FROM VIRAL INFECTIONS Final Rejection Becton, Dickinson and Company
16890372 LATERAL FLOW ASSAY AND METHODS FOR DETECTING HIGH CONCENTRATION ANALYTES Final Rejection Becton, Dickinson and Company
18212168 BIOHAZARD ANALYZER Non-Final OA UNIVERSITY OF UTAH RESEARCH FOUNDATION
18038653 BIOMOLECULE STRUCTURE DETECTION PROBE, BIOMOLECULE STRUCTURE DETECTION KIT, AND METHOD FOR DETECTING BIOMOLECULE STRUCTURE Final Rejection KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION
17599475 ARTERIOSCLEROSIS AND ARTERIOSCLEROSIS-RELATED DISEASE MARKER Non-Final OA National Cerebral and Cardiovascular Center

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month